2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117044
    12(R)-HEPE 109430-12-8 98%
    12(R)-HEPE is a monohydroxy fatty acid synthesized from EPA by the eggs of the sea urchin, S. purpuratus.1 The biological activity of 12(R)-HEPE has not been extensively documented, but may be similar to that of 12(R)-HETE.
    12(R)-HEPE
  • HY-117057
    Hexaenoic acid 105528-06-1 98%
    Very long chain polyunsaturated fatty acids (VLCPUFAs) are important components of ceramides and sphingomyelin and are present in retina, sperm, and brain. Tetratriaconta-16(Z),19(Z),22(Z),25(Z),28(Z),31(Z)-hexaenoic acid is a C34:6 VLCPUFA whose specific biological actions are largely unknown. This VLCPUFA, along with others, has been investigated for its role in activating protein kinase C.
    Hexaenoic acid
  • HY-117110
    Arginylproline 2418-69-1 98%
    Arginylproline (H-Arg-Pro-OH) is a dipeptide consisted of arginine and proline. Arginylproline reduces intracellular triglyceride (TG) levels stimulated by Oleic acid (HY-N1446), through the peptide transporter 1 (PepT1) pathway.
    Arginylproline
  • HY-117131
    ZINC17167211 592539-21-4 98%
    ZINC17167211 is a potent PPAR-α agonist (EC50=0.16 nM) that can be used in the study of diabetes, hyperlipidemia, and inflammatory diseases.
    ZINC17167211
  • HY-117168
    1,2-Dilinoleoyl-sn-glycerol 24529-89-3
    1,2-Dilinoleoyl-sn-glycerol is a diacylglycerol (DAG) with linoleic acid (HY-N0729) (18:2) side chains attached at both the sn-1 and sn-2 positions. It has been found as a component of phosphatidic acid in rat liver mitochondria and in spinach chloroplast membranes. 1,2-Dilinoleoyl-sn-glycerol is upregulated in some pregnant women and has been used as a biomarker to predict later preeclampsia in early pregnancy.
    1,2-Dilinoleoyl-sn-glycerol
  • HY-117201
    Methyl 3-hydroxyoctanoate 7367-87-5 98%
    Methyl 3-hydroxyoctanoate (3-Hydroxy octanoic acid methyl ester) is an ester product.
    Methyl 3-hydroxyoctanoate
  • HY-117219
    SKF 104976 136209-43-3 98%
    SKF 104976 is a 3,2-carboxylic acid derivative with potent 14-alpha-demethylase (14 alpha DM) inhibitory activity. SKF 104976 inhibited 14 alpha DM activity by 50% at 2 nM in Hep G2 cell extracts. SKF 104976 inhibited the incorporation of [14C]acetate into cholesterol in intact cells at similar concentrations, accompanied by accumulation of lanosterol, and resulted in a 40-70% decrease in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) activity. SKF 104976 did not affect the uptake and degradation of low-density lipoprotein in Hep G2 cells, indicating that HMGR and low-density lipoprotein receptor activities are not coordinately regulated under these conditions. The inhibitory effect of SKF 104976 on HMGR activity remained unchanged even when the flux of carbon units in the sterol synthesis pathway was reduced by 80%. SKF 104976 did not inhibit HMGR activity under conditions where sterol synthesis was almost completely blocked by lovastatin.
    SKF 104976
  • HY-117431
    Prostaglandin B3 36614-32-1 98%
    Prostaglandin B3 (PGB3) is a member of the class of prostaglandins B and a secondary alcohol. PGB3 exhibits a rather low affinity to human PPARγ with a Ki value greater than 1 mM compared with Ki values of 26.28 ± 8.7 μM for PGB1 and 77 ± 37.7 μM for PGB2.
    Prostaglandin B3
  • HY-117441
    5(S)-HPEPE 143292-98-2 98%
    5(S)-HPEPE is an ester product.
    5(S)-HPEPE
  • HY-117446
    AS-1669058 1395553-32-8 98%
    AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice.
    AS-1669058
  • HY-117466
    FR186054 179053-90-8 98%
    FR186054 is an oral active acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor with the IC50 of 99 nM. FR186054 shows hypocholesterolemic effect and can be used for study of hypercholesterolemia and atherosclerosis.
    FR186054
  • HY-117562
    a-FABP-IN-1 1310361-52-4 98%
    a-FABP-IN-1 (Compound 5g) is a potent and selective human adipocyte fatty acid-binding protein (a-FABP) inhibitor with a Ki below 1.0 nM. a-FABP-IN-1 inhibits the pro-inflammatory cytokine production.
    a-FABP-IN-1
  • HY-117749
    Bisoxatin acetate 14008-48-1 98%
    Bisoxatin (WY 8138; DB09219) acetate is a laxative agent. Bisoxatin acetate is a stimulant for intestinal peristalsis and has the potential for the research of constipation disorder.
    Bisoxatin acetate
  • HY-117780
    Rawsonol 125111-69-5 98%
    Rawsonol is a brominated diphenylmethane derivative obtained from the green alga Avrainuika rawsoni. Rawsonol exhibits inhibitory activity against 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, with activities related to cholesterol biosynthesis inhibition or other metabolic pathways involving HMG-CoA reductase activity.
    Rawsonol
  • HY-117918
    ST-1892 1409411-32-0 98%
    ST-1892 (compound 14) is a highly potent FXR agonist (EC50=7.2 nM) that can be used to study diseases or disorders caused by metabolic inflammation.
    ST-1892
  • HY-118068
    Methyl 3-hydroxyoctadecanoate 2420-36-2 98%
    Methyl 3-hydroxyoctadecanoate is an ester product.
    Methyl 3-hydroxyoctadecanoate
  • HY-118141
    BMS-194449 170686-12-1 98%
    BMS-194449 is a beta 3 receptor agonist with the Ki value of 160 nM. BMS-194449 can be used for study of obesity and non-insulin dependent diabetes.
    BMS-194449
  • HY-118146
    Cicrotoic acid 25229-42-9 98%
    Cicrotoic acid is an unsaturated fatty acid that increases bile flow and changes lipid composition.
    Cicrotoic acid
  • HY-118210
    PHOP 288862-83-9 98%
    PHOP is a fatty acid amide hydrolase (FAAH) inhibitor used to assess inhibitory activity in a fluorometric assay. PHOP can determine FAAH activity by measuring the amount of 4-pyridin-1-ylbutyric acid released by the enzyme in rat brain microsomes. PHOP demonstrates potential as a FAAH inhibitor and can directly measure FAAH activity by reversed-phase HPLC and fluorescence detection, providing a basis for the development of new inhibitors.
    PHOP
  • HY-118311
    (Z)-W 3699 63250-48-6 98%
    (Z)-W 3699 is a potential choleretic. (Z)-W 3699 can increase the solubility of cholesterol in the gallbladder by altering the secretion of micellar bile acids. (Z)-W 3699 can prevent the formation of cholesterol-containing gallstones in dogs.
    (Z)-W 3699
Cat. No. Product Name / Synonyms Application Reactivity